Eli Lilly
Director - Analytical
Dr Mark Milford is an analytical scientist with over 25 years of industrial experience in the protein analytical field. Having gained a PhD from the University of Southampton (UK), Mark’s industrial experience has spanned analytical roles in development, commercialization and routine manufacture of biopharmaceuticals, most recently in the analytical testing of monoclonal antibody products. Currently holding a position of Director - Analytical with Eli Lilly, based at the Kinsale manufacturing facility, Mark has technical oversight of analytical aspects of new product introduction and commercialization for biopharmaceutical drug substances, both at the Kinsale manufacturing facility and across the Lilly analytical network, overseeing the analytical method lifecycle and driving analytical control strategy.
Mark has a particular interest in analytical procedure development, validation and post-approval lifecycle from a large molecule perspective. As such, Mark held the position of Industry Expert on the ICH Expert Working Group for ICHQ2(R2) / ICHQ14, as well as the current Deputy Topic Lead for the EFPIA ICHQ2(R2) / ICHQ14 Support Group.